These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 11765303

  • 1. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
    Tsikouris JP, Cox CD.
    Pharmacotherapy; 2001 Dec; 21(12):1514-29. PubMed ID: 11765303
    [Abstract] [Full Text] [Related]

  • 2. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J.
    Am J Cardiol; 2003 Mar 20; 91(6A):15D-26D. PubMed ID: 12670638
    [Abstract] [Full Text] [Related]

  • 3. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ, Markham A.
    Drugs; 1999 Dec 20; 58(6):1043-59. PubMed ID: 10651390
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
    Qin D, Leef G, Alam MB, Rattan R, Munir MB, Patel D, Khattak F, Adelstein E, Jain SK, Saba S.
    J Cardiol; 2016 May 20; 67(5):471-6. PubMed ID: 26233885
    [Abstract] [Full Text] [Related]

  • 5. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H, Saliba W.
    Expert Rev Cardiovasc Ther; 2007 Jan 20; 5(1):9-19. PubMed ID: 17187453
    [Abstract] [Full Text] [Related]

  • 6. A benefit-risk assessment of class III antiarrhythmic agents.
    Elming H, Brendorp B, Pehrson S, Pedersen OD, Køber L, Torp-Petersen C.
    Expert Opin Drug Saf; 2004 Nov 20; 3(6):559-77. PubMed ID: 15500415
    [Abstract] [Full Text] [Related]

  • 7. [Atrial fibrillation in heart failure].
    Costard-Jäckle A.
    Herz; 2002 Jun 20; 27(4):378-87. PubMed ID: 12187868
    [Abstract] [Full Text] [Related]

  • 8. Antiarrhythmic drug therapy of atrial fibrillation.
    VerNooy RA, Mounsey JP.
    Cardiol Clin; 2004 Feb 20; 22(1):21-34. PubMed ID: 14994845
    [Abstract] [Full Text] [Related]

  • 9. Drug choices in the treatment of atrial fibrillation.
    Reiffel JA.
    Am J Cardiol; 2000 May 25; 85(10A):12D-19D. PubMed ID: 10822036
    [Abstract] [Full Text] [Related]

  • 10. Potentially significant drug interactions of class III antiarrhythmic drugs.
    Yamreudeewong W, DeBisschop M, Martin LG, Lower DL.
    Drug Saf; 2003 May 25; 26(6):421-38. PubMed ID: 12688833
    [Abstract] [Full Text] [Related]

  • 11. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
    AFFIRM First Antiarrhythmic Drug Substudy Investigators.
    J Am Coll Cardiol; 2003 Jul 02; 42(1):20-9. PubMed ID: 12849654
    [Abstract] [Full Text] [Related]

  • 12. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation.
    Torp-Pedersen C, Brendorp B, Køber L.
    Expert Opin Investig Drugs; 2000 Nov 02; 9(11):2695-704. PubMed ID: 11060831
    [Abstract] [Full Text] [Related]

  • 13. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
    Singh BN, Mody FV, Lopez B, Sarma JS.
    Am J Cardiol; 1999 Nov 04; 84(9A):161R-173R. PubMed ID: 10568677
    [Abstract] [Full Text] [Related]

  • 14. [Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study].
    Niu F, Huang CX, Jiang H, Yang B, Guo WL, Chen YX, Jin CR, Liu ZM.
    Zhonghua Yi Xue Za Zhi; 2006 Jan 10; 86(2):121-3. PubMed ID: 16620720
    [Abstract] [Full Text] [Related]

  • 15. Antiarrhythmic effect of the Ca2+-activated K+ (SK) channel inhibitor ICA combined with either amiodarone or dofetilide in an isolated heart model of atrial fibrillation.
    Kirchhoff JE, Diness JG, Abildgaard L, Sheykhzade M, Grunnet M, Jespersen T.
    Pflugers Arch; 2016 Nov 10; 468(11-12):1853-1863. PubMed ID: 27722784
    [Abstract] [Full Text] [Related]

  • 16. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries.
    Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM, GUSTO-III Investigators.
    Heart; 2002 Oct 10; 88(4):357-62. PubMed ID: 12231591
    [Abstract] [Full Text] [Related]

  • 17. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ.
    N Engl J Med; 1999 Sep 16; 341(12):857-65. PubMed ID: 10486417
    [Abstract] [Full Text] [Related]

  • 18. Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
    Mykytsey A, Bauman JL, Razminia M, Zheutlin T, Wang T, Saleem M, Leal S, Kehoe RF.
    J Cardiovasc Pharmacol Ther; 2007 Mar 16; 12(1):36-43. PubMed ID: 17495256
    [Abstract] [Full Text] [Related]

  • 19. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
    Joseph AP, Ward MR.
    Ann Emerg Med; 2000 Jul 16; 36(1):1-9. PubMed ID: 10874228
    [Abstract] [Full Text] [Related]

  • 20. Hemodynamic effects of antiarrhythmic compounds: intrinsic effects and autonomic modulation.
    Hoffmeister HM, Beyer ME, Seipel L.
    Am J Cardiol; 1997 Oct 23; 80(8A):24G-30G. PubMed ID: 9354409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.